EAGER: Virus-resembling optical nano-materials for intraoperative ovarian cancer imaging

EAGER：用于术中卵巢癌成像的类似病毒的光学纳米材料

• 批准号: 1144237
• 负责人: Bahman Anvari
• 金额: $ 30万
• 依托单位: University of California-Riverside
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2014-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1144237&HistoricalAwards=false
• 关键词: EAGER; Virus; resembling; optical; nano

1144237AnvariThis proposal explores a new class of nanoparticles, thus, may have widespread implications in science and in patient care. Visualizing residual tumor deposits at surgery has the promise of improving patient survival for multiple tumor types, including ovarian cancer. Further, addition of phototherapy has the potential for killing tumor deposits that may be too small to see by the surgeon. Successful outcome of the proposed research activities has direct relevance towards future clinical strategies aimed at staging and treatment of ovarian cancer. At one level, targeted OVGs may be utilized in conjunction with the current standard of practice that consists of open surgical cytoreduction to identify small peritoneal lesions that cannot be identified with existing pre-operative imaging methods (e.g., CT and MRI). Identifying these lesions is detrimental to tumor relapse and patient?s survival. Furthermore, with future advancement in microendoscopy technologies, OVGs may prove useful during laparoscopic procedures aimed at staging and clinical management of ovarian cancer, particularly in high risk individuals due to family history.

1144237 AnvariThis proposal explores a new class of nanoparticles，thus，may have widely implications in science and in patient care.这项提议探索了一类新的纳米颗粒，因此，可能在科学和患者护理方面具有广泛的意义。在手术中观察残留的肿瘤沉积物有希望提高多种肿瘤类型（包括卵巢癌）患者的生存率。此外，增加光疗具有杀死可能太小而不能被外科医生看到的肿瘤沉积物的潜力。拟议的研究活动的成功结果与旨在卵巢癌分期和治疗的未来临床策略直接相关。在一个层面上，靶向OVGs可以与当前的实践标准结合使用，该实践标准包括开放性手术细胞减灭术，以识别用现有的术前成像方法无法识别的小腹膜病变（例如，CT和MRI）。识别这些病变是有害的肿瘤复发和病人？的生存。此外，随着显微内窥镜技术的未来发展，OVG可能在旨在卵巢癌分期和临床管理的腹腔镜手术中证明是有用的，特别是在由于家族史的高风险个体中。